Market Cap
kr.145.4b
Last Updated
2021/05/05 17:16 UTC
Data Sources
Company Financials +
Executive Summary
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. More Details
Rewards
Risk Analysis
No risks detected for GMAB from our risk checks.
Snowflake Analysis
Outstanding track record with flawless balance sheet.
Similar Companies
Share Price & News
How has Genmab's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GMAB is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: GMAB's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
-2.2%
GMAB
-2.1%
DK Biotechs
-0.4%
DK Market
1 Year Return
29.4%
GMAB
27.1%
DK Biotechs
33.6%
DK Market
Return vs Industry: GMAB exceeded the Danish Biotechs industry which returned 28.3% over the past year.
Return vs Market: GMAB underperformed the Danish Market which returned 32.9% over the past year.
Shareholder returns
| GMAB | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.2% | -2.1% | -0.4% |
| 30 Day | 6.5% | 4.7% | 4.3% |
| 90 Day | -10.6% | -8.4% | 4.0% |
| 1 Year | 29.4%29.4% | 27.2%27.1% | 37.1%33.6% |
| 3 Year | 78.7%78.7% | 78.6%74.1% | 60.6%48.2% |
| 5 Year | 122.3%122.3% | 52.7%46.4% | 81.9%58.0% |
Long-Term Price Volatility Vs. Market
How volatile is Genmab's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
How Much Of Genmab A/S (CPH:GMAB) Do Institutions Own?4 weeks ago | Simply Wall St
Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 35%?1 month ago | Simply Wall St
Could The Market Be Wrong About Genmab A/S (CPH:GMAB) Given Its Attractive Financial Prospects?Valuation
Is Genmab undervalued compared to its fair value and its price relative to the market?
38.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GMAB (DKK2223) is trading below our estimate of fair value (DKK3583.89)
Significantly Below Fair Value: GMAB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GMAB is poor value based on its PE Ratio (30.5x) compared to the XE Biotechs industry average (28x).
PE vs Market: GMAB is poor value based on its PE Ratio (30.5x) compared to the Danish market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: GMAB is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: GMAB is overvalued based on its PB Ratio (7.6x) compared to the DK Biotechs industry average (6.3x).
Future Growth
How is Genmab forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
15.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GMAB's forecast earnings growth (15.2% per year) is above the savings rate (0.1%).
Earnings vs Market: GMAB's earnings (15.2% per year) are forecast to grow faster than the Danish market (10.9% per year).
High Growth Earnings: GMAB's earnings are forecast to grow, but not significantly.
Revenue vs Market: GMAB's revenue (13.9% per year) is forecast to grow faster than the Danish market (6.9% per year).
High Growth Revenue: GMAB's revenue (13.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GMAB's Return on Equity is forecast to be high in 3 years time (20.3%)
Past Performance
How has Genmab performed over the past 5 years?
40.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GMAB has high quality earnings.
Growing Profit Margin: GMAB's current net profit margins (47.1%) are higher than last year (40.4%).
Past Earnings Growth Analysis
Earnings Trend: GMAB's earnings have grown significantly by 40.9% per year over the past 5 years.
Accelerating Growth: GMAB's earnings growth over the past year (119.4%) exceeds its 5-year average (40.9% per year).
Earnings vs Industry: GMAB earnings growth over the past year (119.4%) exceeded the Biotechs industry 21.8%.
Return on Equity
High ROE: GMAB's Return on Equity (24.9%) is considered high.
Financial Health
How is Genmab's financial position?
Financial Position Analysis
Short Term Liabilities: GMAB's short term assets (DKK18.8B) exceed its short term liabilities (DKK1.3B).
Long Term Liabilities: GMAB's short term assets (DKK18.8B) exceed its long term liabilities (DKK769.0M).
Debt to Equity History and Analysis
Debt Level: GMAB is debt free.
Reducing Debt: GMAB has not had any debt for past 5 years.
Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Genmab current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GMAB's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Jan van de Winkel (59 yo)
10.92yrs
Tenure
kr.35,200,000
Compensation
Dr. Jan G. J. van de Winkel, Ph.D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board. He is a Co-Founder of Genmab A/S...
CEO Compensation Analysis
Compensation vs Market: Jan's total compensation ($USD5.68M) is above average for companies of similar size in the Danish market ($USD3.69M).
Compensation vs Earnings: Jan's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: GMAB's management team is considered experienced (2.2 years average tenure).
Board Members
Experienced Board: GMAB's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Genmab A/S's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Genmab A/S
- Ticker: GMAB
- Exchange: CPSE
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr.145.416b
- Shares outstanding: 65.36m
- Website: https://www.genmab.com
Number of Employees
Location
- Genmab A/S
- Kalvebod Brygge 43
- Copenhagen
- Capital Region of Denmark
- 1560
- Denmark
Listings
Biography
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the tr...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/05 17:16 |
| End of Day Share Price | 2021/05/05 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.